Revised outcome of Board Meeting held on 17th May, 2025 inter-alia to approve Audited Financial Results for the quarter and year ended 31st March, 2025.
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mangalam Drugs & Organics reported its audited standalone and consolidated results for Q4 and FY ended March 31, 2025. FY25 net sales declined about 13.5% to Rs 31,757.60 lakhs from Rs 36,735.35 lakhs in FY24, reflecting weak top-line performance. Despite the revenue drop, the company swung from a net loss of Rs 904.89 lakhs in FY24 to a net profit of Rs 692.43 lakhs in FY25, with EPS improving to Rs 4.37 from a negative Rs 5.72. Operating profit before other income rose sharply from Rs 276.15 lakhs to Rs 1,942.45 lakhs, indicating significant margin expansion. However, Q4 FY25 was weak with PAT of just Rs 15.09 lakhs versus Rs 354.61 lakhs in Q4 FY24. The statutory auditor (V.S. Somani & Co.) issued an unmodified (clean) opinion with no going concern or emphasis-of-matter issues, and the board also appointed Ragini Chokshi & Co. as Secretarial Auditor for FY24-25.
Positive turnaround signal — the company moved from a loss to a healthy profit with improved operating margins and a clean audit report, though declining revenues and a weak Q4 print may temper near-term sentiment. Shareholders get a clear bottom-line recovery story, but should watch whether the revenue decline reverses in coming quarters.